Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-05 06:41 am Sale | 2024-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | STATE STREET CORP STT | 6,016,227 4.800% | -338,104 (-5.32%) | Filing History |
| 2024-11-14 09:38 am Purchase | 2024-09-30 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | Avoro Capital Advisors LLC | 8,888,888 7.200% | 8,888,888 (New Position) | Filing History |
| 2024-10-16 09:15 am Sale | 2024-09-30 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | STATE STREET CORP STT | 6,354,331 5.100% | -470,780 (-6.90%) | Filing History |
| 2024-04-10 2:03 pm Purchase | 2024-03-28 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | The Vanguard Group | 12,404,050 10.010% | 1,731,974 (+16.23%) | Filing History |
| 2024-02-13 4:58 pm Sale | 2023-12-29 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | The Vanguard Group | 10,672,076 9.930% | -158,357 (-1.46%) | Filing History |
| 2024-01-24 12:57 pm Purchase | 2023-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | STATE STREET CORP STT | 6,825,111 6.350% | 854,767 (+14.32%) | Filing History |
| 2024-01-23 4:14 pm Purchase | 2023-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | BlackRock Inc. BLK | 13,303,281 12.400% | 592,650 (+4.66%) | Filing History |
| 2023-06-09 2:15 pm Purchase | 2023-05-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | The Vanguard Group | 10,830,433 10.130% | 544,261 (+5.29%) | Filing History |
| 2023-02-09 11:07 am Purchase | 2022-12-30 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | The Vanguard Group | 10,286,172 9.700% | 646,029 (+6.70%) | Filing History |
| 2023-02-08 10:08 am Purchase | 2022-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | STATE STREET CORP STT | 5,970,344 5.630% | 1,845,874 (+44.75%) | Filing History |
| 2023-01-26 08:52 am Unchanged | 2022-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | BlackRock Inc. BLK | 12,710,631 12.000% | 0 (Unchanged) | Filing History |
| 2023-01-20 09:43 am Purchase | 2022-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | BlackRock Inc. BLK | 12,710,631 12.000% | 702,568 (+5.85%) | Filing History |
| 2022-02-09 3:24 pm Purchase | 2021-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | The Vanguard Group | 9,640,143 9.220% | 358,592 (+3.86%) | Filing History |
| 2022-01-27 11:00 am Unchanged | 2021-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | BlackRock Inc. BLK | 12,008,063 11.500% | 0 (Unchanged) | Filing History |
| 2022-01-25 3:03 pm Sale | 2021-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | BlackRock Inc. BLK | 12,008,063 11.500% | -555,069 (-4.42%) | Filing History |
| 2021-02-10 10:30 am Sale | 2020-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | The Vanguard Group | 9,281,551 9.030% | -515,956 (-5.27%) | Filing History |
| 2021-01-26 6:52 pm Purchase | 2020-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | BlackRock Inc. BLK | 12,563,132 12.200% | 202,174 (+1.64%) | Filing History |
| 2020-02-14 1:43 pm Sale | 2019-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | RTW INVESTMENTS LP | 0 0.000% | -5,316,156 (Position Closed) | Filing History |
| 2020-02-13 1:58 pm Sale | 2019-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | STATE STREET CORP STT | 4,124,470 4.120% | -949,305 (-18.71%) | Filing History |
| 2020-02-11 7:35 pm Sale | 2019-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR | The Vanguard Group | 9,797,507 9.780% | -1,047,064 (-9.66%) | Filing History |